Navigation Links
Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:4/24/2008

CRANBURY, N.J., April 24 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008, at 2:20 p.m. EDT, at the Ritz-Carlton in Key Biscayne, Florida.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website for 30 days until May 30, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

CONTACTS:

Investors: Media:

John Quirk Cory Tromblee

Porter Novelli Life Sciences Porter Novelli Life Sciences

(212) 601-8296 (617) 897-8294


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Minn. , Dec. 7, 2016  Vyriad Inc. ... to the company,s Board of Directors. ... as we build our business and develop our oncolytic ... cancer therapy," said Stephen Russell , MD, PhD, ... Agnes , share our vision and passion for making ...
(Date:12/7/2016)... 7, 2016  Genprex, Inc. a biopharmaceutical company ... treatments, today announced that it has retained ICR ... strategic communications and advisory firm, to develop and ... will combine investor relations, public relations and digital ... profile of Genprex and its lead candidate Oncoprex, ...
(Date:12/7/2016)... , Dec. 7, 2016  Muse bio, a ... technologies, today announced that Dr. Kevin Ness ... the Board of Directors. Kevin succeeds ... becomes the company,s Chief Science Officer as well as ... Director of the BioDesign Center at the RAS Energy ...
(Date:12/7/2016)... NEW YORK and ANN ARBOR, ... a privately held biopharmaceutical company developing breakthrough immune modulatory ... clinical trial of the Company,s lead therapeutic candidate, LYC-30937- ... Psoriasis is often a debilitating skin disease that is ... the United States , with approximately ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):